These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10191234)

  • 21. Dichotomy in cross-clade reactivity and neutralization by HIV-1 sera: Implications for active and passive immunotherapy.
    Cavacini LA; Duval M; Patil A; Wood C; Mayer KH; Ruprecht RM; Posner MR
    J Med Virol; 2005 Jun; 76(2):146-52. PubMed ID: 15834877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10.
    Mehandru S; Wrin T; Galovich J; Stiegler G; Vcelar B; Hurley A; Hogan C; Vasan S; Katinger H; Petropoulos CJ; Markowitz M
    J Virol; 2004 Dec; 78(24):14039-42. PubMed ID: 15564511
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection.
    Rachinger A; Navis M; van Assen S; Groeneveld PH; Schuitemaker H
    Clin Infect Dis; 2008 Dec; 47(11):e86-9. PubMed ID: 18947331
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibody neutralization and escape by HIV-1.
    Wei X; Decker JM; Wang S; Hui H; Kappes JC; Wu X; Salazar-Gonzalez JF; Salazar MG; Kilby JM; Saag MS; Komarova NL; Nowak MA; Hahn BH; Kwong PD; Shaw GM
    Nature; 2003 Mar; 422(6929):307-12. PubMed ID: 12646921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effector HIV-specific cytotoxic T-lymphocyte activity in long-term nonprogressors: associations with viral replication and progression.
    Keoshkerian E; Ashton LJ; Smith DG; Ziegler JB; Kaldor JM; Cooper DA; Stewart GJ; Ffrench RA
    J Med Virol; 2003 Dec; 71(4):483-91. PubMed ID: 14556259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry.
    Blish CA; Nedellec R; Mandaliya K; Mosier DE; Overbaugh J
    AIDS; 2007 Mar; 21(6):693-702. PubMed ID: 17413690
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of human immunodeficiency virus type 1 IIIB to a neutralization-resistant phenotype in an accidentally infected laboratory worker with a progressive clinical course.
    Beaumont T; van Nuenen A; Broersen S; Blattner WA; Lukashov VV; Schuitemaker H
    J Virol; 2001 Mar; 75(5):2246-52. PubMed ID: 11160728
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection.
    Pilgrim AK; Pantaleo G; Cohen OJ; Fink LM; Zhou JY; Zhou JT; Bolognesi DP; Fauci AS; Montefiori DC
    J Infect Dis; 1997 Oct; 176(4):924-32. PubMed ID: 9333150
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neutralization of multiple HIV-1 isolates from a single subject by autologous sequential sera.
    Tremblay M; Wainberg MA
    J Infect Dis; 1990 Sep; 162(3):735-7. PubMed ID: 2387997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Delineating antibody recognition in polyclonal sera from patterns of HIV-1 isolate neutralization.
    Georgiev IS; Doria-Rose NA; Zhou T; Kwon YD; Staupe RP; Moquin S; Chuang GY; Louder MK; Schmidt SD; Altae-Tran HR; Bailer RT; McKee K; Nason M; O'Dell S; Ofek G; Pancera M; Srivatsan S; Shapiro L; Connors M; Migueles SA; Morris L; Nishimura Y; Martin MA; Mascola JR; Kwong PD
    Science; 2013 May; 340(6133):751-6. PubMed ID: 23661761
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of heterologous neutralizing antibody responses of human immunodeficiency virus type 1 (HIV-1)- and HIV-2-infected Senegalese patients: distinct patterns of breadth and magnitude distinguish HIV-1 and HIV-2 infections.
    Rodriguez SK; Sarr AD; MacNeil A; Thakore-Meloni S; Gueye-Ndiaye A; Traoré I; Dia MC; Mboup S; Kanki PJ
    J Virol; 2007 May; 81(10):5331-8. PubMed ID: 17301136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 Dual Infected LTNP-EC Patients Developed an Unexpected Antibody Cross-Neutralizing Activity.
    Pernas M; Sanchez-Merino V; Casado C; Merino-Mansilla A; Olivares I; Yuste E; Lopez-Galindez C
    PLoS One; 2015; 10(8):e0134054. PubMed ID: 26258485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficient neutralization of primary isolates by the plasma from HIV-1 infected Indian children.
    Prakash SS; Chaudhary AK; Lodha R; Kabra SK; Vajpayee M; Hazarika A; Bagga B; Luthra K
    Viral Immunol; 2011 Oct; 24(5):409-13. PubMed ID: 22004138
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Viral phenotypes and antibody responses in long-term survivors infected with attenuated human immunodeficiency virus type 1 containing deletions in the nef and long terminal repeat regions.
    Verity EE; Zotos D; Wilson K; Chatfield C; Lawson VA; Dwyer DE; Cunningham A; Learmont J; Dyer W; Sullivan J; Churchill M; Wesselingh SL; Gabuzda D; Gorry PR; McPhee DA
    J Virol; 2007 Sep; 81(17):9268-78. PubMed ID: 17567690
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunoglobulin G (IgG) and IgA, but also nonantibody factors, account for in vitro neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by serum and plasma of HIV-infected patients.
    Burrer R; Salmon-Ceron D; Richert S; Pancino G; Spiridon G; Haessig S; Roques V; Barre-Sinoussi F; Aubertin AM; Moog C
    J Virol; 2001 Jun; 75(11):5421-4. PubMed ID: 11333928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection.
    Harrer T; Harrer E; Kalams SA; Elbeik T; Staprans SI; Feinberg MB; Cao Y; Ho DD; Yilma T; Caliendo AM; Johnson RP; Buchbinder SP; Walker BD
    AIDS Res Hum Retroviruses; 1996 May; 12(7):585-92. PubMed ID: 8743084
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neutralizing antibodies and serum interferon levels in the different stages of HIV infection.
    Szabó B; Tóth FD; Kiss J; Ujhelyi E; Füst G; Horváth A; Hollán SR
    Acta Virol; 1990 Apr; 34(2):164-70. PubMed ID: 1975977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Primary isolate neutralization by HIV type 1-infected patient sera in the era of highly active antiretroviral therapy.
    Dreyer K; Kallas EG; Planelles V; Montefiori D; McDermott MP; Hasan MS; Evans TG
    AIDS Res Hum Retroviruses; 1999 Nov; 15(17):1563-71. PubMed ID: 10580407
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control.
    Zaunders J; Dyer WB; Churchill M
    Curr Opin HIV AIDS; 2011 May; 6(3):151-6. PubMed ID: 21378562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.